Esketamine in resistant depression: a case report
European Psychiatry August 27, 2024 L. Carrión Expósito, G. Chauca Chauca, R. Galan Armenteros et al.
In a 62-year-old patient with treatment-resistant major depressive disorder, intranasal esketamine led to marked improvement. From the fifth administration onward, the patient showed clear progress. At three months, the MADRS depression scale score dropped from a baseline of 46 to 14, and at six months to 1, indicating euthymia. The only adverse effect was very mild dizziness after each dose. This case suggests that esketamine can be a fast, safe, and well-tolerated option for patients who do not respond to other treatments.